Citations

Clear

2129 citation(s) found for "Fu, Christine".

Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial
Sise, Meghan E. , Santos, José Ramón, Goldman, Jason D. , Tuttle, Katherine R, Teixeira, J. Pedro , Seibert, A. F., Koullias, Yiannis , Llewellyn, Joe , Zhao, Yang , Hyland, Robert H. , Osinusi, Anu, Winter, Helen , Humeniuk, Rita , Hulter, Henry N., Gottlieb, Robert , Fusco, Dahlene N. , Birne, Rita , Small, Catherine B. , Plate, Markus, McPhail, Mark , Investigators, for the REDPINE, Ballesteros, Rosa , Malheiro, Luís , Silva, Gil, Correia, João Paulo , Vida, Ana Carlota, Silva, André, Carujo, Antonio, Fernandez, Jordi Carratala, Cruzado, Josep M. , Sandoval, Diego , Gimeno, Fransesc Puchades, Gómez‐Muñoz, Neus, Roma, María Martínez, Gallego, Juan Horcajada, Pablo, Castañeda, Silvia, Padilla Urrea, Sergio, Rial Crestelo, David, Santos Fernandez, Jose, Ramon, Benet, Susanna, Benítez, Rosa, Bracke, Carmen, Chamorro, Anna, Graterol, Fredzzia, Lladós, Gemma , Mateu, Lourdes , Rebollo, Boris, Romero, Alba , Soldevila, Laura , Abad, Elena, José, Alba San, Viladomiu, Alex Soriano, Abolnik, Igor Z., Acharya, Anjali , Allen, Leland, Bellovich, Keith, Burton, Mary Jane , Cameron, Miriam L., Criner, Gerard J., Criner, Lii-Yoong H, Lambert, Joseph, Rashid, Marium, Shore-Brown, Heidi, Diaz, George A., Dougherty, David W. , Erdmann, Nathaniel, Berrington, William R., Logar, Christine M., Vadivel, Nidyanandh, Everett, Allison, Lourdes, Gonzalez Suarez Maria, Berhe, Mezgebe , Colbert, Gates B. , Hebert, Christopher, Mehta, Ankit , Spak, Cedric W. , Estrada, Lorie, Vargas, Richard, Pham, Alex, Mason, Lynn, Tallmadge, Catherine, Braddom, Ariana, Nicholas, Melissa, Jamil, Aayla K. , McAllister, Ashley , Guerra, Christina, Sam, Teena , Solis, Edilia, Goyal, Munish, Laurence, Brett, Malhotra, Vinay , Manrique, Luis, McKinnell, James A., McMahon, Blaithin A. , Campbell, Ruth , Morse, Caryn G. , Navarro, Jesús, Ostrosky, Luis, Patel, Bela , Grimes, Carolyn Z. , Hernández, María , Mammadova, Mehriban, Nielsen, Laura, Umana, Virginia, Pusch, Tobias, Schrager, Harry, Mallada, Jason, Siegel, Marc , Slim, Jihad , Apodaca, Krystle D., Harkins, Michelle , Cunningham, Amy, Tuttle, Katherine R, Criner, Gerard J. , Tuttle, Katherine R. , Tuttle, Katherine R , Gottlieb, Robert L , Criner, Gerard , Teixeira, J Pedro , Tuttle, Katherine R, Regan, S. P. , Huang, Hailin , Stancampiano, Fernando F. , Libertin, Claudia R. , Investigators, for the REDPINE, Belhassen‐García, Moncef , Abelenda-Alonso, Gabriela , Rombauts, Alexander , Deltoro, Miguel García , España, Sergio, López, C. , Paredes, Roger , Viladomiu, Alex Soriano, Medjeral‐Thomas, Nicholas , Lobo, Suzana Margareth , Allen, Leland, Lambert, Joseph, Dougherty, David, Hebert, Christopher, Choe, Jennifer, McAllister, Ashley, Gotur, Deepa Bangalore , Koraishy, Farrukh M. , Malhotra, Vinay, Robinson, Philip Alan , Sanyal, Arun J. , Sriram, Peruvemba , Cunningham, Amy G, Tuttle, Katherine R

Mayo Clinic

Clinical Infectious Diseases | June 24, 2024 | Volume: 79 | Issue: 5 | Pages: 1172-1181

10.1093/cid/ciae333 | PMID 38913574 Get It

Abstract Background Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-β-cyclodextrin excipient were evaluated in hospitalized patients with COVID-19 and severe kidney impairment. Methods In REDPINE, a phase 3, randomized, double-blind, placebo-controlled study, participants aged ≥12 years hospitalized for COVID-19 pneumonia with acute kidney injury, chronic kidney disease, or kidney failure were randomized 2:1 to receive intravenous remdesivir (200 mg on day 1; 100 mg daily up to day 5) or placebo (enrollment from March 2021 to March 2022). The primary efficacy end point was the composite of the all-cause mortality rate or invasive mechanical ventilation rate through day 29. Safety was evaluated through day 60. Results Although enrollment concluded early, 243 participants were enrolled and treated (remdesivir, n = 163; placebo, n = 80). At baseline, 90 participants (37.0%) had acute kidney injury (remdesivir, n = 60; placebo, n = 30), 64 (26.3%) had chronic kidney disease (remdesivir, n = 44; placebo, n = 20), and 89 (36.6%) had kidney failure (remdesivir, n = 59; placebo, n = 30); and 31 (12.8%) were vaccinated against COVID-19. Composite all-cause mortality or invasive mechanical ventilation rates through day 29 were 29.4% and 32.5% in the remdesivir and placebo group, respectively (P = .61). Treatment-emergent adverse events were reported in 80.4% for remdesivir versus 77.5% for placebo, and serious adverse events in 50.3% versus 50.0%, respectively. Pharmacokinetic plasma exposure to remdesivir was not affected by kidney function. Conclusions Although the study was underpowered, no significant difference in efficacy was observed between treatment groups. REDPINE demonstrated that remdesivir is safe in patients with COVID-19 and severe kidney impairment. Clinical Trials Registration EudraCT 2020-005416-22; Clinical Trials.gov NCT04745351.
An Allergic Reaction in Contrast-enhanced Ultrasound Lymphography for Lymphovenous Bypass Surgery
Rames, Jess D. , Tran, Nho V. , Hesley, Gina K. , Fahradyan, Vahe , Lee, Christine U. , Fahradyan, Vahe

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | June 17, 2024 | Volume: 12 | Issue: 6 | Pages: e5908

10.1097/gox.0000000000005908 | PMID 38911583 Get It

Summary: Lymphedema following oncologic intervention can cause significant lifelong morbidity for patients in whom conservative management fails. The associated swelling, discomfort, pain, and recurrent cellulitis greatly diminish quality of life. Surgical procedures, including suction-assisted lipectomy, lymphovenous anastomosis (LVA), and vascularized lymph node transfers, show effectiveness in both volume reduction in affected extremities and symptom relief. However, the success of procedures like LVA is dependent on effective preoperative lymphatic mapping to identify suitable vessels for anastomosis. Traditional superficial lymphatic mapping uses near infrared fluorescence indocyanine green (ICG) imaging. Moreover, recent advances in contrast-enhanced ultrasound (CEUS) lymphography increased lymphovenous bypass target identification for LVA in the extremities.7 CEUS lymphography uses microbubbles as a contrast-enhancing agent injected intradermally into the affected extremity with subsequent identification of superficial collecting lymphatic vessels using ultrasound. Although a recent report noted an uptick in severe and critical adverse drug reactions to an ultrasound contrast agent injected intravenously in stress echocardiography, adverse drug reactions associated with ultrasound contrast-enhancing agents in body ultrasound are rare. The safety profile and potential complications from CEUS lymphography in the lymphedema population have yet to be fully characterized. In this case report, the authors present the first cutaneous adverse drug event following a secondary exposure to the contrast used for CEUS imaging. Mechanisms and justifications for an immune-mediated process are explored, and a review of similar manifestations in other related contrast applications is discussed.
Multi‐center study on sellar reconstruction after endoscopic transsphenoidal pituitary surgery
Ali, Hawa M. , Leland, Evelyn M. , Stickney, Emily, Lohse, Christine M. , Iyoha, Ehiremen, Valappil, Benita, Filimonov, Andrey , Goetschel, Kaitlin , Young, Sarah C. , Shahin, Maryam N. , Sanusi, Olabisi , Sonfack, Davaine Joel Ndongo , Champagne, Pierre‐Olivier , Zwagerman, Nathan T. , Gardner, Paul A. , Zenonos, Georgios A. , Link, Michael J. , Peris‐Celda, Maria , Stokken, Janalee K., Stokken, Janalee K. , Wang, Eric W , Snyderman, Carl H , Van Gompel, Jamie, Choby, Garret , Carlson, Matthew L , Nadeau, Sylvie , Geltzeiler, Mathew , Gompel, Jamie J. Van , Choby, Garret , Pinheiro‐Neto, Carlos

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1558-1567

10.1002/alr.23382 | PMID 38884280 Get It

AbstractIntroductionSurgical techniques for sellar reconstruction include no reconstruction, use of synthetic materials, autologous grafts, and/or vascularized flaps. The aim of this study was to conduct a multi‐center study comparing the efficacy and postoperative morbidity associated with different sellar reconstruction techniques.MethodsA retrospective chart review of patients who underwent endoscopic transsphenoidal surgery for pituitary tumors from five participating sites between January 2021 and March 2023 was performed. The variables included demographics, tumor characteristics, reconstruction technique, postoperative cerebrospinal fluid leak (CSF) leak, and 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores. Comparisons of postoperative complications, SNOT‐22 scores, and duration of surgery by type of onlay reconstruction were evaluated using Fisher's exact test, analysis of variance, and Kruskal‒Wallis test.ResultsFive hundred and one patients were identified. The median tumor size was 2.1 cm, and 64% were non‐functioning. Intraoperative CSF leak was identified in 38% of patients. A total of 89% of patients underwent onlay reconstruction: 49% were reconstructed with mucosal grafts, 35% with nasoseptal flaps, and 5% with other onlay techniques. Nasoseptal flaps were utilized more frequently in the setting of giant pituitary adenomas (>3 cm), medial cavernous sinus wall resection, and high‐flow intraoperative CSF leaks. Cases who utilized mucosal grafts had an overall shorter operating time (median: 183 min vs. 240 min; p < 0.001). Five postoperative CSF leaks were identified, and therefore, statistical analysis could not be performed for this complication.ConclusionThe effectiveness and morbidity of different sellar reconstruction techniques are comparable. Vascularized flaps were utilized more frequently in the setting of larger tumors and high‐flow intraoperative CSF leaks.
Microfluidic Digital Immunoassay for Point-of-Care Detection of NT-proBNP from Whole Blood
Chen, C.-H. , Zhou, Xiaoyan , Snozek, Christine L.H. , Chen, Chao , Zhou, Xiaoyan , Snozek, Christine Lh, Wang, Shaopeng , Porter, Ryan, Yang, Eric H. , Wang, Shaopeng

Mayo Clinic

Analytical Chemistry | June 15, 2024 | Volume: 96 | Issue: 26 | Pages: 10569-10576

10.1021/acs.analchem.4c01046 | PMID 38877973 Get It

3D‐Printed Hollow Microneedles Array with Luer Lock Connection for Facile and Painless Intradermal Injection: A Proof of Concept
Ghaznavi, Amirreza , Xu, Jie , Lee, Christine U. , Hara, Seth A. , Xu, Jie

Mayo Clinic

Advanced Materials Technologies | June 15, 2024 | Volume: 9 | Issue: 18 | Pages: No page available

10.1002/admt.202400286 Get It

AbstractA 3D‐printed array of hollow microneedles (HMNs) is designed and fabricated using a high‐resolution stereolithography 3D printer and assembled with a 3D‐printed reservoir that incorporates a Luer lock mechanism, ensuring standard and secure connection to syringes. The proof‐of‐concept needle designs consist of half‐eccentric and concentric conical tip shapes, each arrayed with two different interspacing values. After the geometrical features of the devices are characterized, the devices are tested ex vivo in porcine skin to evaluate the impact of tip shape and interspacing on the depth of penetration and the efficacy of the devices in delivering fluids (such as tattoo ink) into the dermis. Overall, the 3D‐printed HMNs can deliver fluids into the target layer of skin. Refinement of the design is ongoing with the ultimate aim to provide alternatives for intradermal drug delivery and diagnostic imaging, such as superficial lymphography.
Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Ahsan, Aarif, Mantis, Christine, Luo, Xizhi, Zhang, Catherine, Valdes, Cesar Rodriguez , Voorhees, Peter M. , Safah, Hana, McKay, John T., Korde, Neha , Vij, Ravi , Kumar, Shaji , Bueno, Orlando Felix, Pothacamury, Rajvineeth Kumar, D’Souza, Anita , Chung, Alfred , Tuchman, Sascha Alexander , McKay, John, Weisel, Katja C , Teipel, Raphael , Bueno, Orlando F. , Talati, Chetasi , Ross, Jeremy A.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7532-7532

10.1200/jco.2024.42.16_suppl.7532 Get It

7532 Background: ABBV-383 is a BCMA x CD3 bispecific antibody with 2 high-affinity BCMA-binding domains and a low-affinity CD3 engaging arm that has been shown to decrease the negative impact of soluble BCMA (sBCMA) and drive sustained T-cell activation with reduced cytokine release in preclinical models of MM. Here, we describe correlative biomarker results of baseline and longitudinal sBCMA levels and immune profiles in the ongoing first-in-human trial that supports 60 mg Q4W as the optimal therapeutic dose of ABBV-383 monotherapy. Methods: Peripheral blood and serum samples from patients with RRMM enrolled in the phase 1 open-label, dose-expansion study (NCT03933735) who received ABBV-383 at 20, 40, or 60 mg Q3W or 60 mg Q4W were collected at baseline (post-dexamethasone, pre–ABBV-383), on treatment, and at disease progression. Samples were analyzed by flow cytometry for immune cell populations, Luminex for cytokines, and electrochemiluminescence ligand binding for sBCMA. Results: Median sBCMA levels at baseline were highly variable among patients, but did not associate with clinical response (≥ partial response [PR]) to ABBV-383 at the selected optimal dose level of 60 mg Q4W (<PR: 244.7 ng/mL; ≥PR: 52.2 ng/mL; P=0.13). Reduction in sBCMA levels over time associated with clinical response (Cmin at cycle 5: <PR, 244.7 ng/mL; ≥PR, 4.7 ng/mL; P=0.04). ABBV-383 treatment led to a rapid and transient increase of proinflammatory cytokines, including IL-6, IL-8, IL-10, TNF-α (Cmax within cycle 1: 29, 349.5, 1375, 456.5 pg/mL, respectively), and promoted T-cell redistribution (89% reduction of CD8+ T cells from periphery), activation (1.9-fold increase in CD69+CD8+ T cells), and proliferation (2-fold increase in Ki67+CD8+ T cells) within cycle 1 in 60-mg Q4W-treated patients. The frequency of baseline CD8+ T-cell exhaustion (PD-1/TIM3) did not impact clinical response at the optimal dose level of 60 mg Q4W ABBV-383 (<PR: 3.5%; ≥PR: 3.9%; P=0.9). Peak induction levels of proinflammatory cytokines during cycle 1 correlated with occurrence of cytokine release syndrome (≥G1) as well as clinical response across dose levels. Conclusions: High-avidity BCMA binding coupled to low-affinity T-cell engagement distinguishes the resulting mechanism of action for ABBV-383. Responses to 60 mg Q4W ABBV-383 were independent of baseline sBCMA levels and resulted in rapid and transient proinflammatory cytokine production that promoted robust T-cell redistribution, activation, and proliferation, indicating that the optimal dose of ABBV-383 maximizes its clinical potential as a convenient, safe, and effective therapy for MM. Clinical trial information: NCT03933735 .
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Camidge, D. Ross , Bar, Jair , Goldman, Jonathan W. , Moiseenko, Fedor , Филиппова, Е. А. , Çiçin, İrfan , Daaboul, Nathalie , Liu, Chunling , Bradbury, Penelope A., Moskovitz, Mor, Katgı, Nuran , Cuppens, Kristof , Wu, Shang‐Yin , Baijal, Shobhit , Kuo, Chih‐Hsi S. , Planchard, David , Baik, Christina S. , Li, Martha, Ansell, Peter , Xia, Summer, Bolotin, Ellen, Looman, Jim, Ratajczak, Christine K. , Horinouchi, Hidehito , Goldman, Jonathan W , Moiseenko, Fedor , Cicin, Irfan , Zer Kuch, Alona , Girard, Nicolas , Cuppens, Kristof , Han, Ji-Youn , Wu, Shang-Yin , Mansfield, Aaron S , Kuo, Chih-Hsi , Nishino, Kazumi , Lee, Se-Hoon , Planchard, David , Lu, Shun , Filippova, Elena, Ciuleanu, Tudor–Eliade , Tomasini, Pascale , Girard, Nicolas , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 25 | Pages: 3000-3011

10.1200/jco.24.00720 | PMID 38843488 Get It

PURPOSE Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536 ) aimed to identify the optimal c-Met protein–overexpressing non–small cell lung cancer (NSCLC) population for treatment with Teliso-V (stage I) and expand the selected group for efficacy evaluation (stage II). Stage II enrolled patients with nonsquamous epidermal growth factor receptor ( EGFR )-wildtype NSCLC. METHODS Eligible patients had locally advanced/metastatic c-Met protein–overexpressing NSCLC and ≤2 previous lines of therapy (including ≤1 line of systemic chemotherapy). c-Met protein overexpression in nonsquamous EGFR -wildtype NSCLC was defined as ≥25% tumor cells with 3+ staining (high [≥50% 3+]; intermediate [≥25%–<50%]). Teliso-V was administered at 1.9 mg/kg once every 2 weeks. The primary end point was overall response rate (ORR) by independent central review. RESULTS In total, 172 patients with nonsquamous EGFR -wildtype NSCLC received Teliso-V in stages I and II. ORR was 28.6% (95% CI, 21.7 to 36.2; c-Met high, 34.6% [95% CI, 24.2 to 46.2]; c-Met intermediate, 22.9% [95% CI, 14.4 to 33.4]). The median duration of response was 8.3 months (95% CI, 5.6 to 11.3; c-Met high, 9.0 [95% CI, 4.2 to 13.0]; c-Met intermediate: 7.2 [95% CI, 5.3 to 11.5]). The median overall survival was 14.5 months (95% CI, 9.9 to 16.6; c-Met high, 14.6 [95% CI, 9.2 to 25.6]; c-Met intermediate, 14.2 [95% CI, 9.6 to 16.6]). The median progression-free survival was 5.7 months (95% CI, 4.6 to 6.9; c-Met high, 5.5 [95% CI, 4.1 to 8.3]; c-Met intermediate: 6.0 [95% CI, 4.5 to 8.1]). Most common any-grade treatment-related adverse events (AEs) were peripheral sensory neuropathy (30%), peripheral edema (16%), and fatigue (14%); the most common grade ≥3 AE was peripheral sensory neuropathy (7%). CONCLUSION Teliso-V was associated with durable responses in c-Met protein–overexpressing nonsquamous EGFR -wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable.
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Arteaga, Carlos L. , Chandarlapaty, Sarat , Desmedt, Christine , Sasano, Hironobu , Sireci, Anthony , Sandoval, Cynthia, Won, Helen , Litchfield, Lacey M. , Turner, Nicholas C. , Loi, Sherene , Johnston, Stephen , Graff, Stephanie L. , Goetz, Matthew P. , Liu, Deli , Rodrik-Outmezguine, Vanessa S.

Mayo Clinic

Journal of Clinical Oncology | June 5, 2024 | Volume: 42 | Issue: 17_suppl | Pages: LBA507-LBA507

10.1200/jco.2024.42.17_suppl.lba507 Get It

LBA507 Background: In monarchE (NCT03155997), 2 years of adjuvant abemaciclib + ET resulted in sustained improvement in invasive disease-free survival (IDFS; HR=0.680, 7.6% absolute benefit at 5 years) in patients (pts) with HR+, HER2-, node-positive, high-risk EBC. Here, we investigate the prognostic value of ctDNA detection and dynamics in pts from monarchE. Methods: Samples were analyzed from a selected pt subset (n=1397; abemaciclib + ET arm, n=685; ET arm, n=712), enriched for overall IDFS events compared to the total monarchE study population (IDFS event rate: 31% [433/1397] vs 18% [992/5637]). Pts had blood collected pre-study treatment (baseline) and at 3, 6, or 24 months. ctDNA detection was performed using the personalized, tumor informed Signatera ctDNA assay (Natera, Inc) and whole exome sequencing (WES) of matched primary tumor and normal required for assay design was performed. Results: Among 1397 pts, 65% (n=910) had sufficient plasma samples and WES performed, and all 910 had successful ctDNA assay testing. Among these 910 pts, the IDFS event rate was 27% (abemaciclib + ET, 23% [101/438]; ET alone, 31% [146/472]). Rates of ctDNA positivity (at baseline and any change from baseline) and associated IDFS events are shown in Table. Among pts with ctDNA positivity, 87% had an IDFS event in comparison to 15% with persistent ctDNA negative (-) status during the study. Conclusions: In a pt subset from monarchE enriched for IDFS events, ctDNA detection was relatively infrequent (<20%); however, its detection at any time during the 24 months of study therapy was adversely prognostic. As compared to pts who had remaining ctDNA positive (+), pts who had clearance of ctDNA on therapy had lower risk of IDFS events, but the event risk still remained clinically meaningful in these pts. Clinical trial information: NCT03155997 . [Table: see text]
Pulmonary Hypertension Across the Spectrum of Left Heart and Lung Disease
Larive, Brett , Beck, Gerald J. , Erzurum, Serpil C. , Farha, Samar , Finet, J. Emanuel , Highland, Kristin B. , Jacob, Miriam , Jellis, Christine , Renapurkar, Rahul D., Singh, Harsimran , Vanderpool, Rebecca , Wilcox, Jennifer , Yu, Shilin , Hill, Nicholas S. , Vanderpool, Rebecca R , Wilcox, Jennifer D , Borlaug, Barry A. , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Mehra, Reena , Tang, W.H. Wilson

Mayo Clinic

European Journal of Heart Failure | June 4, 2024 | Volume: 26 | Issue: 7 | Pages: 1642-1651

10.1002/ejhf.3302 | PMID 38837273 Get It

Abstract Aims Patients with pulmonary hypertension (PH) are grouped based upon clinical and haemodynamic characteristics. Groups 2 (G2, left heart disease [LHD]) and 3 (G3, lung disease or hypoxaemia) are most common. Many patients display overlapping characteristics of heart and lung disease (G2–3), but this group is not well-characterized. Methods and results Patients with PH enrolled in the prospective, NHLBI-sponsored PVDOMICS network underwent intensive clinical, biomarker, imaging, gas exchange and exercise phenotyping. Patients with pure G2, pure G3, or overlapping G2–3 PH were compared across multiple phenotypic domains. Of all patients with predominant G2 (n = 136), 66 (49%) were deemed to have secondary lung disease/hypoxaemia contributors (G2/3), and of all patients categorized as predominant G3 (n = 172), 41 (24%) were judged to have a component of secondary LHD (G3/2), such that 107 had G2–3 (combined G2/3 and G3/2). As compared with G3, patients with G2 and G2–3 were more obese and had greater prevalence of hypertension, atrial fibrillation, and coronary disease. Patients with G2 and G2–3 were more anaemic, with poorer kidney function, more cardiac dysfunction, and higher N-terminal pro-B-type natriuretic peptide than G3. Lung diffusion was more impaired in G3 and G2–3, but commonly abnormal even in G2. Exercise capacity was severely and similarly impaired across all groups, with no differences in 6-min walk distance or peak oxygen consumption, and pulmonary vasoreactivity to nitric oxide did not differ. In a multivariable Cox regression model, patients with G2 had lower risk of death or transplant compared with G3 (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.30–0.86), and patients with G2–3 also displayed lower risk compared with G3 (HR 0.57, 95% CI 0.38–0.86). Conclusions Overlap is common in patients with a pulmonary or cardiac basis for PH. While lung structure/function is clearly more impaired in G3 and G2–3 than G2, pulmonary abnormalities are common in G2, even when clinically judged as isolated LHD. Further study is required to identify optimal systematic evaluations to guide therapeutic innovation for PH associated with combined heart and lung disease. Clinical Trial Registration: ClinicalTrials.gov NCT02980887.